Econdisc

Morgan Stanley reduced its price target on the shares of Mylan N.V. (NASDAQ: MYL) following downward revision to its estimates due to the IMS trends, generic price pressure and uncertain new launch timing. Meanwhile, in a separate note, Mylan announced its NDA for TLD, a combo of Lamivudhine...